58/100BOracle stock forecast 2027–2031
Analysts' average 12-month price target for Oracle is 230.19, 86.0% above the current price of 123.79. Their targets range from 95.00 to 325.00.
Of the 31 firms that rated Oracle in the past 12 months, 29 rate it buy or strong buy, 2 hold and 0 sell or strong sell (each firm at its latest rating); on average they come to Buy.
Analysts' 1-year price targets range from 95.00 to 325.00, with an average of 230.19.
| Strong buy | 0 | |
| Buy | 29 | |
| Hold | 2 | |
| Sell | 0 | |
| Strong sell | 0 |
12-month price target
| Highest target | 325.00 |
| Average target | 230.19 |
| Lowest target | 95.00 |
| Current price | 123.79 |
Oracle price target history
Have analysts recently raised or lowered their Oracle price target and rating?
How analysts rate Oracle, month by month
29 of 31 firms rate it buy now, against 23 of 30 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Oracle analyst upgrades, downgrades and price targets
The latest rating change came on 2 November 2026, when Stephens upgraded Oracle from Equal Weight to Overweight. Its price target is 213.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 2 Nov 2026 | Stephens Brett Huff | Upgraded · Equal Weight → Overweight | 213.00 | — | 130.68 |
| 29 Oct 2026 | Scotiabank Pat Colville | — | 241.00 → 205.00 | -14.9% | 139.92 |
| 29 Oct 2026 | Robert W. Baird Rob Oliver | — | 315.00 → 215.00 | -31.7% | 144.34 |
| 29 Oct 2026 | Melius Research Ben Reitzes | — | 160.00 → 170.00 | +6.3% | 144.34 |
| 26 Oct 2026 | Wells Fargo Michael Turrin | Reiterated · Overweight | 280.00 → 250.00 | -10.7% | 126.16 |
| 23 Oct 2026 | Goldman Sachs | Reiterated · Buy | 240.00 → 206.00 | -14.2% | 125.51 |
| 11 Sept 2026 | BMO Capital Keith Bachman | Reiterated · Outperform | 220.00 → 195.00 | -11.4% | 155.88 |
| 11 Sept 2026 | Stifel Nicolaus Brad Reback | Reiterated · Buy | 220.00 → 200.00 | -9.1% | 153.17 |
| 11 Sept 2026 | Barclays | Reiterated · Overweight | 250.00 → 252.00 | +0.8% | 153.17 |
| 11 Sept 2026 | KeyBanc | — | 300.00 → 285.00 | -5.0% | 153.17 |
| 4 Sept 2026 | Morgan Stanley Sanjit Singh | Reiterated · Equal Weight | 207.00 → 210.00 | +1.4% | 154.04 |
| 2 Sept 2026 | Jefferies Brent Thill | Reiterated · Buy | 320.00 → 290.00 | -9.4% | 141.26 |
| 12 Aug 2026 | Bernstein Mark Moerdler | — | 325.00 → 95.00 | -70.8% | 148.91 |
| 6 Aug 2026 | UBS Karl Keirstead | Reiterated · Buy | 285.00 → 245.00 | -14.0% | 144.36 |
| 20 Jul 2026 | CLSA Bhavtosh Vajpayee | — | 145.00 | — | 126.48 |
| 11 Jun 2026 | D.A. Davidson | — | 180.00 → 225.00 | +25.0% | 180.22 |
| 11 Jun 2026 | Wedbush | Reiterated · Outperform | 275.00 → 240.00 | -12.7% | 201.26 |
| 11 Jun 2026 | BMO Capital Keith Bachman | Reiterated · Outperform | 205.00 → 220.00 | +7.3% | 201.26 |
| 11 Jun 2026 | Bernstein Mark Moerdler | Reiterated · Outperform | 313.00 → 325.00 | +3.8% | 201.26 |
| 11 Jun 2026 | Piper Sandler | Reiterated · Overweight | 240.00 → 225.00 | -6.3% | 201.26 |
| 11 Jun 2026 | Scotiabank Pat Colville | Reiterated · Sector Outperform | 290.00 → 241.00 | -16.9% | 201.26 |
| 11 Jun 2026 | Wolfe Research Alex Zukin | — | 225.00 | — | 201.26 |
| 11 Jun 2026 | Barclays Raimo Lenschow | Reiterated · Overweight | 230.00 → 250.00 | +8.7% | 201.26 |
| 11 Jun 2026 | MoffettNathanson | — | 325.00 | — | 201.26 |
| 8 Jun 2026 | Oppenheimer Brian Schwartz | Reiterated · Outperform | 235.00 → 275.00 | +17.0% | 213.41 |
| 8 Jun 2026 | Evercore ISI Kirk Materne | Reiterated · Outperform | 385.00 → 245.00 | -36.4% | 213.41 |
| 5 Jun 2026 | Cantor Fitzgerald | Reiterated · Overweight | 229.00 → 284.00 | +24.0% | 220.15 |
| 4 Jun 2026 | RBC Capital | — | 160.00 → 190.00 | +18.8% | 236.34 |
| 3 Jun 2026 | Mizuho Securities Siti Panigrahi | — | 400.00 → 320.00 | -20.0% | 244.54 |
| 2 Jun 2026 | UBS Karl Keirstead | Reiterated · Buy | 280.00 → 285.00 | +1.8% | 239.41 |
| 2 Jun 2026 | Scotiabank Pat Colville | Reiterated · Sector Outperform | 215.00 → 290.00 | +34.9% | 248.07 |
| 13 May 2026 | Wedbush | Reiterated · Outperform | 225.00 → 275.00 | +22.2% | 187.74 |
| 12 May 2026 | Oppenheimer Brian Schwartz | Reiterated · Outperform | 235.00 | — | 193.83 |
| 7 May 2026 | Arete Research | — | 255.00 | — | 193.99 |
| 24 Apr 2026 | Wedbush | — | 225.00 | — | 176.28 |
| 23 Apr 2026 | Morgan Stanley Keith Weiss | Reiterated · Equal Weight | 213.00 → 207.00 | -2.8% | 175.66 |
| 11 Mar 2026 | Deutsche Bank Brad Zelnick | — | 375.00 → 300.00 | -20.0% | 162.32 |
| 11 Mar 2026 | RBC Capital Rishi Jaluria | Reiterated · Sector Perform | 195.00 → 160.00 | -17.9% | 163.12 |
| 11 Mar 2026 | Stifel Nicolaus Brad Reback | Reiterated · Buy | 275.00 → 220.00 | -20.0% | 163.12 |
| 11 Mar 2026 | JP Morgan | Upgraded · Neutral → Overweight | — | — | — |
| 9 Mar 2026 | Scotiabank | Reiterated · Sector Outperform | 220.00 → 215.00 | -2.3% | 151.56 |
| 9 Mar 2026 | Cantor Fitzgerald Thomas Blakey | — | 320.00 → 229.00 | -28.4% | 151.56 |
| 9 Mar 2026 | Barclays Raimo Lenschow | Reiterated · Overweight | 310.00 → 230.00 | -25.8% | 151.56 |
| 5 Mar 2026 | Jefferies Brent Thill | — | 400.00 → 320.00 | -20.0% | 154.67 |
| 25 Feb 2026 | Oppenheimer | Upgraded · Perform → Outperform | — | — | — |
| 9 Feb 2026 | Melius Research Ben Reitzes | — | 370.00 → 160.00 | -56.8% | 156.56 |
| 9 Feb 2026 | Bernstein | — | 339.00 → 313.00 | -7.7% | 142.79 |
| 9 Feb 2026 | DA Davidson | Upgraded · Neutral → Buy | — | — | — |
| 4 Feb 2026 | BMO Capital | — | 270.00 → 205.00 | -24.1% | 147.05 |
| 3 Feb 2026 | Scotiabank | Reiterated · Sector Outperform | 260.00 → 220.00 | -15.4% | 155.02 |
Oracle EPS and revenue estimates
Analysts expect Oracle's EPS to grow 39.1% a year until 2029, faster than over the last 5 years (5.1% a year) and the last 3 years (23.8%).
Analysts expect Oracle's revenue to grow 39.0% a year until 2029, faster than over the last 5 years (10.7% a year) and the last 3 years (10.5%).
Revenue
EPS
Does Oracle beat earnings estimates?
On average, analysts' EPS estimate was 6.4% off the result, either way, and their revenue estimate 1.0%, over the last 12 quarters.
- EPS beats
- 85 / 117
- Revenue beats
- 75 / 110
- Average EPS surprise, last 12
- +5.8%
- Since
- June 1994
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q1 FY2027 | 10 Sept 2026 | 1.74 | 1.92 | +10.3% | 19.13B | 19.35B | +1.1% |
| Q4 FY2026 | 10 Jun 2026 | 1.96 | 2.11 | +7.7% | 19.10B | 19.18B | +0.4% |
| Q3 FY2026 | 10 Mar 2026 | 1.70 | 1.79 | +5.3% | 16.93B | 17.19B | +1.6% |
| Q2 FY2026 | 10 Dec 2025 | 1.64 | 2.26 | +37.8% | 16.19B | 16.06B | -0.8% |
| Q1 FY2026 | 9 Sept 2025 | 1.48 | 1.47 | -0.7% | 15.04B | 14.93B | -0.8% |
| Q4 FY2025 | 11 Jun 2025 | 1.64 | 1.70 | +3.7% | 15.58B | 15.90B | +2.1% |
| Q3 FY2025 | 10 Mar 2025 | 1.49 | 1.47 | -1.3% | 14.38B | 14.13B | -1.7% |
| Q2 FY2025 | 9 Dec 2024 | 1.48 | 1.47 | -0.7% | 14.12B | 14.06B | -0.4% |
| Q1 FY2025 | 9 Sept 2024 | 1.33 | 1.39 | +4.5% | 13.23B | 13.31B | +0.6% |
| Q4 FY2024 | 11 Jun 2024 | 1.65 | 1.63 | -1.2% | 14.56B | 14.29B | -1.9% |
| Q3 FY2024 | 11 Mar 2024 | 1.38 | 1.41 | +2.2% | 13.29B | 13.28B | -0.0% |
| Q2 FY2024 | 11 Dec 2023 | 1.32 | 1.34 | +1.5% | 13.05B | 12.94B | -0.8% |
Oracle stock price 2027–2031: scenarios
If Oracle's earnings keep growing at the 27.1% a year analysts expect to FY2029, it would earn about 25.33 a share in FY2031. At the P/E it has traded at over the last five years (28.9 to 41.8) that is 731.61 to 1,058.18 a share, or 872.18 at its average P/E of 34.4. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2027 | 8.14 | 235.10 | 280.27 | 340.04 |
| FY2028 | 11.09 | 320.37 | 381.92 | 463.37 |
| FY2029 | 15.67 | 452.73 | 539.71 | 654.81 |
| FY2030 (extrapolated) | 19.93 | 575.52 | 686.09 | 832.41 |
| FY2031 (extrapolated) | 25.33 | 731.61 | 872.18 | 1,058.18 |
Each year's EPS is the analysts' consensus to FY2029; the years after continue its 27.1% a year. Bear, base and bull apply the lowest, average and highest P/E of the last five fiscal year ends (28.9, 34.4, 41.8).
Is Oracle stock undervalued or overvalued?
Oracle's P/E of 19.1 is near the bottom of its 5-year range (18.2 to 74.0, median 31.4). Analysts do not expect slower growth than in recent years, so it is cheaper than its usual level. Buyers pay less for each point of growth than usual: a PEG of 0.5 on expected growth against 6.2 on its median P/E and past five years' growth. Growing 39.1% a year, Oracle earns a P/E of 25.0 at a PEG of 1 (at most 25): × the next twelve months' EPS of 9.42, a fair value of 235.44; the price, 123.79, is 47.4% below it. Its forward P/E, on the consensus for FY2027, is 15.2.
Fair value on growth is a P/E equal to the EPS growth analysts expect a year (a PEG of 1, at most 25) times the earnings per share of the next twelve months; the ends of the bar are a PEG of 0.75 and 1.25 (a P/E of 18.8 and 31.3). The price against its P/E range
- Price to earnings ratio (TTM)
- 19.10
- Five-year median P/E
- 31.44
- Five-year P/E range
- 18.2 – 74.0
- Forward P/E (FY2027)
- 15.21
- PEG ratio
- 0.70
- To the average target
- +86.0%
Most undervalued US stocks
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 66.390 | 128.2462Price 66.39185 | +93.2% | |
| 101.860 | 195.27146Price 101.86244 | +91.7% | |
| 200.280 | 359.04269Price 200.28449 | +79.3% | |
| 227.150 | 406.28305Price 227.15508 | +78.9% | |
| 159.100 | 284.37213Price 159.10355 | +78.7% | |
| 105.320 | 175.76132Price 105.32220 | +66.9% |
Furthest below the fair value on each stock's page, updated every day.